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Executive summary   
• Clinical decision-making tools can be considered in two broad categories 
– those designed to be used by clinicians and those designed to promote 
shared decision making with the clinician and patient together. 
• The potential effect of computerised clinical decision support systems 
(CDSS) on variations in practice is not well understood, and CDSS are 
currently not a recommended means of improving evidence-based 
practice, or patient outcomes, since the mechanisms of success and 
failure are not well defined and the potential impact on workflows and 
adverse events are poorly evaluated. 
• Despite numerous randomised controlled trials, there is poor quality 
evidence for the effect of CDSS on processes of care and patient 
outcomes. 
• There is moderate-high quality evidence for the role of patient decision 
aids in preference-sensitive and shared decision making contexts. 
• Recommendations for Commonwealth action: 
(i) Develop and implement CDSS standards, and ensure they align 
with evidence-based guidelines. 
(ii) Exercise caution over broader implementation of CDSS until their 
strengths and weaknesses are better understood. 
(iii) Encourage the development and implementation of shared 
decision-making tools for preference-sensitive decisions. 
(iv) Show leadership in the development of provider and consumer 
awareness and training, which should be developed alongside the 
tools themselves. 
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How effective are clinical decision-making tools in improving the quality of health care?: 
A short overview  
Clinical decision-making tools can be considered in two broad categories: those designed to be 
used by clinicians, and those designed to promote shared decision making with the clinician and 
patient together.  
 
There are many forms of evidence summaries and clinical risk prediction tools currently available 
to Australian clinicians. Their quality varies, and the way they are used at the point of clinical 
decision-making is ad hoc and not well defined. When components of them have been included in 
broader decision support systems (usually computerised) these are referred to as computerised 
clinical decision support systems (CDSS). 
 
In a recent series of systematic reviews of the evidence on CDSSs, which summarised over one 
hundred randomised controlled trials, experts found that they had variable effects on processes of 
care, and limited impact on patient outcomes.(1) Despite all these studies, experts point out that 
there is very little evidence on the mechanisms underpinning the success and failure of CDSS, their 
impact on workflow and provider concentration levels, and the possibility of adverse events 
occurring.(2, 3) 
 
With the increasing computerisation of Australian clinical practice, numerous versions of CDSS are 
currently available through proprietary software programs. Standards Australia has established an 
e-health sub-committee to develop standards in this area. (13)  In the absence of standards, an 
evaluation of seven prescribing systems in Australian general practice reported poor linkage to 
evidence-based guidelines, poor quality and the potential to increase prescribing errors. (4) 
 
Clinical decision-making tools designed to facilitate shared decision-making between the clinician 
and their patients are mostly used where:  
• evidence is uncertain;  
• there are multiple options to be weighed up; and  
• the patients’ preferences are important.  
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These are sometimes called preference-sensitive decisions and many would argue that they 
comprise a large percentage of clinical decisions in daily practice, exemplifying the true definition 
of ‘evidence-based practice’.  
 
The standards for evidence-based patient decision aids (International Patient Decision Aid 
Standards) have recently been updated (5), and they provide a useful framework for developing 
clinical decision-making tools. We already know, however, that patient decision aids help patients 
make more informed decisions that are more likely to be consistent with their preferences or 
‘values’.(6) At an individual-patient-level, patient decision aids are also ethical and beneficial with 
no documented evidence of harms. (6, 7) They tend to result in patients choosing more conservative 
management options (such as reduced PSA testing and reduction in elective surgery for some 
conditions), but caution is needed in extrapolating early evidence that they result in system-wide 
cost savings. (8) They should be recommended for improving evidence-based practice, patient 
outcomes and variations in preference-sensitive care. 
 
Australia lags behind countries, such as the UK, in developing policies that facilitate shared 
decision-making for preference-sensitive decisions. However, the existing evidence on clinical 
decision-making tools suggests that there is an urgent need to develop and implement standards 
for CDSS before rolling them out more broadly because their strengths and weaknesses are not 
well understood.  
We recommend the development of a broader policy on clinical decision-making tools with an 
initial focus on tools to facilitate shared decision-making, since these have been shown to be 
effective and there has been no evidence of harms. The role of decision-making tools in decisions 
about effective care (i.e. where the evidence is clear that the benefits outweigh the harms) 
remains an issue of dissemination of evidence and we would urge any policy in this field to be 
considered in the broader context of organisation of care and effective strategies to improve 
quality. 
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What are clinical decision-making tools?   
Decision-making tools are electronic or paper-based supports to assist clinicians and their patients 
make decisions. They commonly assist the patient (and clinician) to go through several necessary 
steps: listing the options available; quantifying the benefits and harms of each; and then ensuring 
that the patient’s preferences are articulated, and then incorporated, into the final decision. They 
can be clinician-mediated, shared, or patient-mediated.  
 
Clinical decision-making tools primarily designed to be used by clinicians 
 
These are decision tools aimed at clinicians, to help provide them with information required for 
shared decision making. They include the summary of findings tables in systematic reviews; risk 
prediction charts (such as for cardiovascular risk, fracture risk, and breast cancer risk); and a large 
number of clinical prediction tools and algorithms. Some are paper-based, and others electronic. 
 
There are also many types of what are known as computerised decision-support systems (CDSSs) 
that may include (or link to) some of the above tool types. CDSSs have been defined as 
‘information systems for improving clinical decision-making’. They may include some or all of the 
following components: a mechanism for healthcare staff or patients to enter patient 
characteristics, or alternatively, electronic medical records may be queried to retrieve these; 
individual patient data may be matched to a knowledge base (e.g. clinical practice guidelines) and 
software algorithms then produce patient-specific assessments and/or recommendations. (1) 
 
Clinical decision-making tools designed to be used by patients or by clinicians and patients together  
 
For many clinical decisions, the clinician should not be the sole decision maker, but rather the 
clinician and patient should, in partnership, make the decision after an informed discussion about 
the relevant issues. This consultation process is referred to as “shared decision making” and is 
where clinicians and patients jointly participate in making a health decision, having discussed the 
options, their benefits and harms, and considered the patient’s values, preferences, and 
circumstances. (9) It is a process that can be used to guide decision making about many health 
decisions, such as screening, tests, and treatments. It can also be thought of as a mechanism for 
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applying evidence with an individual patient through personalising the clinical decision. Shared 
decision making is seen internationally as a hallmark of good clinical practice, an ethical 
imperative, (7) and a way of enhancing patient engagement and activation. (10) It is increasingly 
being advocated for in clinical guidelines and healthcare policies. 
 
The types of decision-making tools described in the above section, while useful for helping 
clinicians to be aware of the evidence and make decisions about options, do not typically map well 
onto decision points in a consultation, nor do they promote patient interaction and discussion. (2) 
Shared decision making can be particularly useful in the following clinical decision-making 
contexts: 
 
(i) where the evidence is uncertain; 
(ii) where there is not one option that is clearly superior to all others  (i.e. the majority 
of clinical decisions); and 
(iii) where benefits and harms need to be weighed up with patient preferences and 
clinical contexts to individualise decisions. (11) 
 
Specifically-developed decision-support tools can help to operationalise the evidence into clinical 
decisions and encourage clinicians to share the decision-making process with their patients. This 
category of decision-support tools take a number of formats, with some examples listed in Table 1 
(see next page). Some are explicitly designed to facilitate shared decision making (e.g. decision 
aids). Others provide some of the information needed for some components of the shared 
decision-making process referred to above (clinician-focussed decision aids), or provide ways of 
initiating or structuring conversations about health decisions (e.g. communication frameworks, 
question prompt lists). These decision-support tools can be used in various ways: during the 
consultation; as ‘homework tools’ (where the patient is invited to use them either in the waiting 
room or at home, before or after the consultation); and either with or without assistance.  
 
Decision-support tool use is not always straightforward: they may not fit the patient’s clinical or 
personal circumstances; clinicians and patients need to be willing to use them; they require 
clinicians to have some skills in how to use them; and there may need to be support for their use 
 6   
and delivery. Decision support tools alone are not the answer, and providing them does not 
guarantee that shared decision making will occur. Barriers and facilitators to implementation often 
lie at the individual clinician level with lack of knowledge/skills, poor clinician-patient relationships, 
and lack of time and/or motivation. However, many system-level barriers also need to be 
addressed, particularly in the multidisciplinary setting where poor communication, lack of trust 
between disciplines and lack of visibility/accessibility to tools exist. (12)  
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Table 1: Examples of types of decision support tools that can be used to facilitate shared decision-
making 
Type of tool  Brief description Examples 
Condition-specific tools 
Decision aids 
 
Describe the options, the benefits and harms of 
each option, along with a values clarification 
exercise and sometimes a guide to decision-
making. 
[For information about assessing the quality of 
decision aids, see http://ipdas.ohri.ca/]  
Ottawa Hospital Research 
Institute Inventory of 
Decision Aids 
(decisionaid.ohri.ca/AZinvent.php) 
 
Decision (fact) 
Boxes 
 
Short summary of the benefits and harms of an 
intervention, often presented in two columns.   
Drug fact box 
(dartmed.dartmouth.edu/spring08/html
/disc_drugs_we.php) 
Decision box 
(decisionbox.ulaval.ca/index.php?id=810
&L=2) 
Option Grids 
 
A one-page summary of the evidence about the 
possible options, addressing patient-centred 
outcomes and questions/concerns frequently 
asked by patients. Can be useful within the 
consultation for a patient to highlight what is 
important to them. 
Option Collaboration 
(optiongrid.org) 
Question prompt 
lists  
A pre-defined list of condition-specific questions 
for patients to consider using in a consultation. 
Question prompt lists for 
cancer patients  
(cancerinstitute.org.au/patient-
support/what-i-need-to-ask) 
Evidence 
summaries  
Clinical practice guidelines and other summaries 
of the body of evidence. 
Clinical Evidence 
(clinicalevidence.bmj.com)  
Up-To-Date (uptodate.com) 
Generic tools 
Communication 
frameworks 
 
Provide a generic set of questions or scripts and 
a structure for clinicians and patients to use 
during decision-making. 
Ask, Share, Know   
(askshareknow.com.au) 
Ottawa Personal Decision 
Guide 
(decisionaid.ohri.ca/decguide.html) 
 
What types of clinical decision-making support tools are commonly used in Australia? 
 
There is currently no systematic way of determining what types of clinical decision-making support 
tools are used in Australia, or how commonly they are used by clinicians and their patients. 
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Clinical decision-making tools designed for clinicians 
 
CDSSs are probably more common in Australia as a result of computerisation of clinical practice 
and medical records in both hospital-based and general practice settings in recent years. For 
example, Standards Australia has established a Clinical Decision Support Sub-Committee to 
‘coordinate, develop, disseminate and promote standards for Clinical Decision Support (CDS) 
information technology in Australia and contribute to the development and harmonisation of 
international CDS standards’.(13) They claim that there is a readiness and partial uptake of CDS in 
Australia, particularly around medication management. However they note that there are 
numerous third party add-ons from vendors and organisations such as the RACGP without 
adequate guarantees of applicability across products, and no nationally agreed governance or 
responsibility to maintain and update these. 
  
In general practice, a limited evaluation of seven clinical software programs in Australia showed 
that CDS features for safe prescribing were not well implemented in these programs. This 
evaluation by a collaboration between the National Prescribing Service (NPS), La Trobe and 
Monash Universities, the Medical Software Industry Association and the Royal Australian College 
of General Practitioners in 2008, audited the seven most commonly used general practice 
programs for 50 features previously rated as having high impact on quality and safety in 
healthcare. They found that 34-62% of features were fully implemented, 18-26% were partially 
implemented and 18-40% were not implemented. In particular, linkage to evidence-based drug 
and therapeutic information was limited, as were patients’ resources and medicine lists, which 
were described as sub-optimal. During prescribing there was potential for medicine mis-selection 
in some systems and linking a medicine with its indication was optional. (14) The seven programs 
evaluated (Best PracticeTM, GenieTM, Medical Director 2TM, Medical Director 3TM, MedTech32TM, 
PractixTM, and ProfileTM) account for 90% of prescribing software in Australian general practice. 
The results of this evaluation were fed back to the industry but we could not find a subsequent 
evaluation of the impact of this activity. 
 
Most of these programs include prescribing components that link to the Monthly Index of Medical 
Specialties (MIMS), Therapeutic Guidelines (TG) and/or the Australian Medicines Handbook 
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(AMH). Some also included risk calculators such as absolute cardiovascular risk but are not linked 
to guidelines or recommendations. A qualitative study of 27 GPs in 2008 found that the 
integration of MIMS, TG and AMH were valued and used but that cost was an issue and 
subscriptions and licences were not always up to date. Participants in this study also highlighted 
the danger of drug and allergy ‘alert-fatigue’ with the risk of clicking through or even turning off 
warnings and alert systems. (4) 
 
It has also been suggested that many existing CDSSs in Australian general practice may actually be 
distracting and potentially harmful through poor design. (15) The authors of this paper recommend 
a minimum set of safety features be included in all software programs including ‘alerts for 
contraindicated drugs, drug dosage support, (e.g. paediatric dosage, dosage if renal impairment, 
warnings for potentially harmful doses), and timely warnings about newly identified medicine 
safety issues. These and other types of decision-support should be underpinned by high quality, 
up-to-date information, and be implemented in such a way that they fit with work flow and are 
easy to use.’ 
 
The Victorian government is exploring policies around CDSS (mainly for hospital settings) with an 
underpinning assumption that CDSS will ‘improve patient care and reduce errors’, although they 
admit a lack of clear standards and governance on this matter. (16) These proposed developments 
include improved diagnostic algorithms and prescribing systems. The NSW Health Department’s 
Clinical Information Access Portal (CIAP) provides state-employed health-workers with access to 
evidence-based databases, journals, clinical practice guidelines and protocols. The Western 
Australian Government’s e-Health program is also being phased in and is planned to include CDSS 
for cardiology, gastroenterology and nephrology. We could not find any evaluation of these.  
 
There is also a range of decision-support tools best described as ‘clinical reference tools’ available 
to Australian clinicians but most require subscription for access.  Many of these are high quality, 
regularly updated and evidence-based but information about Australian subscribers and rates of 
utilisation are not publicly available. It is likely that some individual clinicians and their employers 
have subscriptions to these tools. Such decision-support tools include Best Practice (BMJ), Up-to 
date, DynaMed and others. They are designed to be evidence-based point-of-care reference tools 
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that can be accessed from a computer or hand-held mobile device. There are also a number of 
clinical risk prediction tools available free on the websites of organisations such as the absolute 
cardiovascular risk calculator on the National Heart Foundation site, and Breast and Ovarian 
Cancer Risk tool on Cancer Australia’s website, and there are numerous others nationally and 
internationally. To what extent clinicians know about these tools, access them or use them, 
remains unknown.    
 
Clinical decision-making tools designed for clinicians & patients to use together 
 
These are widely available on the Internet and it is difficult to know to what extent Australians are 
using them. There is a fairly comprehensive inventory of patient decision aids online at the Ottawa 
Health Research Institute (https://decisionaid.ohri.ca/AZinvent.php) most of which have been 
evaluated against the International Patient Decision Aid Standards (IPDAS) and some of these 
developed and evaluated by Australian researchers.  
 
Although Australian researchers have been leaders in the research field of shared decision making, 
it is only recently that this work has started to reach policy and possible implementation in 
Australia. (17) The UK on the other hand, already has a comprehensive and advanced policy and 
programs of implementation in this field (www.patient.co.uk). (18) Recently however, the 
Australian Commission on Safety and Quality in Healthcare has commenced some programs in 
Shared Decision-Making as part of its commitment to supporting patient-centred care and to 
complement their work on reducing unwarranted variations in medical practice and ensuring 
appropriateness of care (http://www.safetyandquality.gov.au/our-work/shared-decision-
making/).  
 
From personal communication, we know that one patient decision aid developed for the NHMRC, 
to assist women deciding whether to take hormone replacement therapy for menopausal 
symptom control, had over 75,000 copies printed and distributed between 2004-2006, and has 
since been available online (number of downloads not known by the authors). (19) Anecdotally we 
also know that an Australian-developed online decision aid for parents with concerns about the 
safety of MMR vaccination has been well received and widely used by Australian immunisation 
 11   
providers and their patients. (20, 21) A more comprehensive evaluation of uptake and use of patient 
decision-support tools in Australia has not been completed.  
What does the national and international evidence say on the effectiveness of various 
clinical decision-making tools?  
Promoting evidence-based practice  
Clinical decision-making tools designed for clinicians  
 
There was a comprehensive systematic review of more than one hundred randomised controlled 
trials of CDSSs completed and published in 2011. (1) The authors looked at the effects of CDSSs in 
six different clinical decision contexts resulting in a six-article series of papers with the following 
results on ‘process of care’. 
 
- Primary preventive care (41 RCTs) (22): There was some evidence that CDSS improved the 
screening of appropriate patients for cardiovascular risk factors and the implementation of 
evidence-based guidelines for CVD risk reduction by clinicians. All nine trials showed an 
increase in targeted CVD assessment and three showed improved management of 
hyperlipidaemia. However there were mixed results for cancer screening (five out of ten 
trials showed an increase in appropriate referral to screening), mental health screening and 
management (two out of six trials showed an increase in discussion of domestic violence), 
immunisation and other preventive care evidence (six out of ten trials showed improved 
ordering of vaccinations, prophylactic aspirin and heparin prescriptions etc). See the 
following section for their effect on patient outcomes and therefore caution about 
recommending their use at this stage. 
 
- Chronic disease management (55 RCTs) (23): Twenty five of the 55 included trials improved 
processes of care such as measurement of HbA1c, BP, BMI, foot surveillance, smoking and 
exercise status at specified times, prescription of antiplatelet medication, lipid 
measurement, pneumococcal and influenza vaccination in diabetics and, to some extent 
for CVD risk reduction. However this effect was not replicated for processes of care in 
asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiac care, 
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cancer and others. The mechanisms behind systems’ success or failure are understudied 
and make it difficult to clearly recommend their use at this stage. 
 
- Therapeutic drug monitoring and dosing (33 RCTs) (24): There was some evidence that 
insulin dosing and vitamin K antagonists dosing were improved by CDSS but the longer-
term sustainability of this is unknown. Systems need to be evaluated against costs and 
workflow and no specific system can be recommended at this stage. 
 
-   Acute care management (36 RCTs) (25): Once again, just over half of the studies showed an 
improvement in processes of care particularly through the use of medication dosing 
assistants, management assistants with alerts and reminders, management assistants using 
guidelines and algorithms and diagnostic assistants. These reduced inappropriate 
medication for elderly patients in ED, improved accurate administration of insulin in 
critically ill patients, improved intraoperative antibiotic re-dosing, prescriptions consistent 
with evidence-based recommendation in children with upper respiratory tract infections in 
outpatients, appropriate antibiotic treatment in hospital patients generally, improved 
documentation of diagnosis of patients admitted to orthopaedics ward, timely 
measurement of blood glucose according to protocols. Although processes of care may 
have improved in some acute care situations, patient outcomes were less likely to be 
measured and far less likely to show positive results (see below). 
 
- Drug prescribing and management (65 RCTs) (26): Once again CDSS improved processes of 
care in more than half of the studies but seldom impacted on patient outcomes. There are 
potentially negative impacts on workflow with these systems as some trials reporting 
clinically inappropriate reminders and one trial stopped early because of a 40% error rate. 
 
- Diagnostic test ordering behaviour (35 RCTs) (27): Just over half of the studies improved test 
ordering behaviour and four systems designed to reduce unnecessary test ordering 
achieved that. As with other applications of CDSSs, it is unclear what determines success or 
failure of these systems and there is only minimal data on adverse events, user satisfaction 
and impacts on workflow.  
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Other types of clinical decision-making tools designed for use by clinicians such as clinical 
prediction rules and clinical reference tools have not been rigorously evaluated for their impact on 
processes of care. (28, 29) 
 
Clinical decision-making tools designed for use by clinicians & patients together 
 
The latest update of the Cochrane review of the effect of patient decision aids for screening and 
treatment decisions now includes 115 RCTs. (6) When considering their effect on evidence-based 
practice, many would argue that shared decision making exemplifies evidence-based practice as it 
was originally defined – integrating the best available evidence with clinical expertise and patients 
preferences and values. (30) With this definition in mind, patient decision aids do increase 
evidence-based practice as they significantly increase patient knowledge, improve accuracy of risk 
perception, and result in a higher proportion of patients choosing an option that is congruent with 
their values. (6) 
Reducing unnecessary variation in the quality of care 
 
Arguably the world’s leading expert on variations in medical practice is John Wennberg, the US 
epidemiologist who developed the Dartmouth Atlas. He has spent his career highlighting and 
studying how we might reduce unwarranted variations in clinical practice. He describes the 
importance of considering clinical care in three categories (see below) when evaluating practice 
variation and considering the implications for clinicians, patients and policymakers.  
 
Effective care is defined as interventions for which the benefits far outweigh the risks; in this case 
the “right” rate of treatment is 100% of patients defined by evidence-based guidelines to be in 
need, and unwarranted variation is generally a matter of underuse.  
 
Wennberg proposes that the most effective way to reduce most of this kind of variation is to have 
stronger primary care systems and better care coordination. (31) 
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Preference sensitive care is when more than one generally accepted treatment option is available, 
such as elective surgery; here, the right rate should depend on informed patient choice, but 
treatment rates can vary extensively because of differences in professional opinion.  
 
The best approach to reducing this type of variation is through shared decision making. Clinical 
decision-making tools such as patient decision aids generally result in patients choosing a more 
conservative option, such as less back surgery and less PSA screening for prostate cancer once 
they are better informed. (6, 31) 
 
Supply sensitive care comprises clinical activities such as doctor visits, diagnostic tests, and hospital 
admissions, for which the frequency of use relates to the capacity of the local healthcare system.  
 
Once again, Wennberg proposes that better care coordination and stronger integration between 
primary and secondary care within organized health systems holds the key to reducing this kind of 
variation. (31) 
Improving patient outcomes  
Clinical decision-making tools designed for clinicians 
 
In most of the 100+ trials of CDSSs, patient-relevant outcomes were rarely assessed. Of the studies 
that did measure patient outcomes, many showed no impact, despite some improvement in 
processes of care. (22, 24-27) The most promising improvement in patient outcomes, however, came 
from CDSS use in diabetic patients where there was some component of patient feedback or 
coaching, combined with physician reminders and recommendations. This was not replicated in 
other chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD), but 
those CDSS systems did not include an active patient component. (23) 
 
The potential harms of CDSS to patients is understudied and under-reported, although a small 
number of studies have shown an increase in prescribing errors with CDSS compared with usual 
care. (26) A meta-regression of these studies found that systems presenting advice in electronic 
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charting or order entry system interfaces were less likely to be effective (OR 0.37, 95% CI 0.17 to 
0.80). (32) Systems were more likely to succeed if they: 
 
a) provided advice for patients in addition to practitioners (OR 2.77, 95% CI 1.07 to 7.17); 
b) required practitioners to supply a reason for over-riding advice (OR 11.23, 95% CI 1.98 to 
63.72); or 
c) were evaluated by their developers (OR 4.35, 95% CI 1.66 to 11.44). (32) 
 
Clinical decision-making tools designed for clinicians & patients to use together 
 
As outlined earlier, tools in this category have generally been developed for decisions where the 
evidence is uncertain, where several options are available and/or where the patients’ preferences 
and values need to be considered. Many would argue this applies to the majority of clinical 
decisions made. The greatest body of evidence is for the effect of patient decision aids, (6) but 
other tools such as option grids, decision boxes etc. often contain similar components and have an 
overlapping purpose, albeit slightly different formats.  
 
The international research community in this field has developed a set of standards: the 
International Patient Decision Aid Standards (IPDAS). These have drawn on the body of scientific 
knowledge about decision-making theory, cognitive psychology, human design and technology, 
evidence-based medicine and implementation science. The purpose of the standards is to improve 
the quality of patient decision aid development and design. 
 
A recent paper has shown a correlation between tools with higher IPDAS ratings and a positive 
impact on patient knowledge of outcome probabilities – i.e. a more informed decision. (33) A 
recent update on the evidence behind these standards has resulted in a series of articles within a 
special supplement (see Table 2). (5) 
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Table 2: Topics covered in the recent IPDAS update series 
Systematic development process 
Disclosure of conflicts of interest 
Providing information about options 
Basing information on comprehensive, critically appraised, and up-to-date synthesis of the 
scientific evidence  
Balancing the presentation of information and options 
Presenting qualitative information about decision outcomes 
Clarifying values 
Addressing health literacy 
Coaching and guidance 
A critical review of the role of patient stories 
Delivering patient decision aids on the Internet 
Establishing effectiveness: key constructs and measurement instruments 
Implementation 
 
The IPDAS collaboration was established in 2003 to ‘enhance the quality and effectiveness of 
patient decision aids by establishing an evidence-informed framework their content, 
development, implementation and evaluation.’ Over the past decade, this group has established 
background documents on 12 core dimensions, originally established by a Delphi process and the 
development of the IPDAS checklist (74 items), the IPDAS qualifying (6 items), certifying (6 items+ 
4 for screening) and quality criteria (28 items). (5) 
 
The recently updated Cochrane review of patient decision aids for treatment and screening 
decisions now includes 115 RCTs. The summary of findings table for this review using GRADE 
shows: 
 
- high quality evidence that patient decision aids increase knowledge compared with usual 
care (Mean 13.5, 95% CI 11.2-15.5);  
- moderate quality evidence that accuracy of risk perception is improved (RR 1.82 95% CI 
1.17-1.97) 
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- low quality evidence of congruence between the chosen option and patient values (RR 1.51 
95% CI 1.17-1.97) 
- high quality evidence of reduced decisional conflict on the uninformed subscale – i.e. 
patients felt more informed (Mean 7.26 95% CI 9.73-4.78) 
-  high quality evidence of reduced decisional conflict on the unclear values subscale – i.e. 
patient felt clearer about their values (Mean 6.09 95% CI 8.50-3.67) 
- moderate quality evidence of increased involvement in decision making (RR 0.66 95% CI 
0.53-0.81). 
 
Understandably, decision aids have a variable effect on choice, but the Cochrane review also 
showed that generally people are more likely to choose conservative options, such as less 
discretionary surgery and less PSA screening for prostate cancer. There are no apparent adverse 
effects on health outcomes or patient satisfaction. They significantly increase patient-provider 
communication. Eight trials have measured the impact on health using the Short Form Health 
Survey (SF-36) with three showing an improvement in physical and emotional domains in the 
decision aid groups. There was no effect on mental or social domain scores. 
 
It has also been shown that patient decision aids have a greater effect on patients with lower 
baseline knowledge levels, and there is increasing interest in their potential role in improving 
health literacy. (33)  
 
Thus, there is good quality evidence that patient decision aids improve informed decision-making 
and patient involvement in clinical decisions. This is particularly important given the findings that 
CDSS for clinicians had limited impact on clinical outcomes unless active patient components were 
included. There is a picture emerging within this body of evidence that the clinician-patient 
partnership is crucial to the effectiveness of clinical decision-making tools. Targeting one side of 
this partnership alone will have limited impact on health outcomes. (34) 
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Are clinical decision-making support tools a recommended means of achieving the above 
objectives? 
 
CDSS is currently not a recommended means of improving evidence-based practice or patient 
outcomes since the mechanisms of success and failure are not well defined and the potential 
impact on workflows and adverse events are poorly evaluated. The potential effect of CDSS on 
variations in practice is not well understood. Where they do have an impact on clinical outcomes, 
it is generally only when an active patient component is included.  
 
There are many tools designed for clinicians to assist with clinical risk prediction and point-of-care 
access to evidence summaries that have the potential to improve evidence-based practice, patient 
outcomes and reduce variations in effective care practices. Access to these often remains 
restricted for Australian clinicians by subscriptions, and those which are free of charge are not 
systematically collated or rated for quality, making it difficult for clinicians to ‘trust’ to ‘access’ and 
to ‘use’ them.  
 
If evidence-based practice is defined as the ‘integration of best available evidence with clinical 
expertise and patient preferences’ then good quality patient decision aids are a recommended 
means of increasing evidence-based practice and patient outcomes for some clinical decision 
contexts, through improving patients’ knowledge about the evidence and facilitating choices that 
are more likely to be congruent with their preferences or ‘values’. They are also recommended as 
a means for reducing preference-sensitive variations in clinical practice. However, more broadly, 
the implementation of shared decision making has proved challenging with a recent systematic 
review showing that clinicians barriers, such as workflow challenges, and most commonly 
‘indifference’, were problematic in many models that relied on them referring patients to these 
resources. (35) 
What is the quality of evidence?  
 
Despite numerous randomised controlled trials of CDSSs, there is poor quality evidence for their 
effect on processes of care and patient outcomes. It remains uncertain what components of these 
systems lead to success, and which lead to failure. 
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There is moderate-high quality evidence for the role of patient decision aids in preference-
sensitive and shared decision making contexts. The evidence for effective implementation of these 
tools is less clear.  
What are the implications for policy and practice?  
 
Given the rapid computerisation of clinical practice, and the ad hoc implementation of various 
CDSSs in Australia, the development of standards for this field and closer alignment and linkage 
with evidence-based guidelines is an important policy issue. 
 
Improving the uptake of resources that can inform clinicians’ decision-making, such as clinical 
prediction and risk tools and point-of-care evidence summaries, is unlikely to occur through 
clinical decision-making tools alone. The extensive work of the Cochrane Effective Practice and 
Organisation of Care (EPOC) group has shown that broader strategies also need to be deployed 
through activities such as audit and feedback, continuing education and so on. Any policy on the 
role of clinical decision-making tools for the Australian system should consider this broader 
context.  
 
Clinical decision-making tools, particularly shared decision-making tools that incorporate 
components of the IPDAS criteria, should be more readily accessible and implemented in 
Australian clinical practice for preference-sensitive decisions. The UK approach to developing a 
policy and program for implementation of shared decision-making and relevant high quality 
patient decision aids should be considered for the Australia setting. However, it is important to 
realise some of the potential barriers from organisations and providers through unfamiliarity and 
‘indifference’. Provider and consumer awareness and training in the use and appraisal of these 
tools should be developed alongside the tools themselves. There needs to be a sustainable 
approach to maintaining and updating these tools to ensure their ongoing safety and use.  
What are the cost implications for health care providers and the health system of 
increasing the uptake of clinical decision-making tools?  
Some of the CDSS studies reported the financial costs as part of their results. In summary the 
effect of these systems was mixed, with some resulting in savings, some having no effect, and 
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some increasing costs. As mentioned earlier, there has been very little research on the impact of 
such tools on workflow and provider concentration/levels of distraction, which is an important 
issue to address.  
 
Similarly the financial costs of patient decision aids have only been measured in a small number of 
studies and the impact on costs has been variable. (6, 8) A recent sub-analysis of economic analyses 
of the Cochrane review of patient decisions (6) included seven studies. (8) It found that four out of 
the seven analyses predicted system-wide savings with the predicted savings ranging from USD8 
to USD3058 per patient. However, the authors note that the quality of these studies was low-
moderate and the risk of bias high. Mixed methodologies were used with evaluations over short 
periods only and an absence of incremental cost-effectiveness ratios. They concluded that: 
“Although there is evidence to show that patients choose more conservative approaches when 
they become better informed, there is insufficient evidence, as yet, to be confident that the 
implementation of patient decision support interventions leads to system-wide savings’. (8)   
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